NCT01795001已完成不适用
The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 460
- 试验地点
- 1
- 主要终点
- cytokine levels
研究概览
简要总结
The purpose of this study is to gain further insights into the molecular pathogenesis of Fuchs' endothelial corneal dystrophy (FECD), to identify targets for potential specific drug therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •normal corneas (including enucleations for uveal melanoma)
- •non-FECD oedematous corneas
排除标准
- •prior irradiation therapy for uveal melanoma
- •corneal extension of uveal melanoma
结局指标
主要结局
cytokine levels
时间窗: at time of prelevation (once, no intervention)
dosage of cytokine levels in aqueous humour (exploratory, non-interventional study)
gene expression levels
时间窗: at time of prelevation (once, no intervention)
microarray expression analysis, reverse transcriptase - quantitative polymerase chain reaction (RT-qPCR), RNA-sequencing (exploratory, non-interventional study)
protein content
时间窗: at time of prelevation (once, no intervention)
immunohistochemistry and immunofluorescence
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Complex Molecular Etiology and Cellular Landscape of Hip OsteoarthritisOsteoarthritis, HipRheumatoid ArthritisNCT05278520University of Turku110
招募中
早期 1 期
To explore the molecular mechanism of chronic urticaria with syndrome of dampness and heat in the intestines and stomach from the perspective of gastrointestinal microecological imbalancechronic urticariaITMCTR2022000023Guang'anmen Hospital, China Academy of Chinese Medicine Sciences
已完成
不适用
Molecular Phenotypes for Cystic Fibrosis Lung DiseaseLung DiseasesCystic FibrosisNCT01116414University of North Carolina, Chapel Hill152
已完成
不适用
Fuchs' Endothelial Dystrophy: Clinical Characteristics, Treatment Outcome, and PathologyFuchs' Endothelial Corneal DystrophyNCT01979250Aarhus University Hospital81
撤回
早期 1 期
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast CancerBreast CancerNCT00993642Tulane University Health Sciences Center